Progressive Supranuclear Palsy (PSP): A Tough Nut to Crack

Since John Steele, John Richardson, and Jerzy Olszewski first described Progressive Supranuclear Palsy (PSP) in 1964, the neuroscience community has been on the lookout to find a “miracle molecule” or an “elixir” that can cure patients diagnosed with this debilitating disease. With more than 2,000 research studies published so far, the domain has garnered significant attention from researchers, but there is no cure for terminal illness, so far. As per our research, nearly 15 clinical-stage PSP investigational programs (highlighted below), have been discontinued, in the last two decades. In 2019, owing to the failure to meet the desired endpoints, two big pharma players, Abbvie and Biogen announced their decision to terminate the development of their pipeline anti-tau antibodies for PSP, namely ABBV-8E12 and gosuranemab, respectively.

Leave a Reply